Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Rosetta Genomics Stories

2011-10-11 07:01:00

PHILADELPHIA and REHOVOT, Israel, Oct. 11, 2011 /PRNewswire/ -- Rosetta Genomics (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, today announced that it has executed a license agreement with Avatao Biotech, a leading biotechnology company developing and distributing cutting-edge diagnostic products in China, for the exclusive rights to market miRview® mets and miRview® mets(2) , Rosetta's microRNA-based...

2011-09-08 07:00:00

PHILADELPHIA and REHOVOT, Israel, Sept. 8, 2011 /PRNewswire/ -- Rosetta Genomics (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, today announced today announced that the Company will participate in the Rodman & Renshaw 13th Annual Global Investment Conference taking place September 12-13, 2011 at the Waldorf Astoria Hotel in New York City. Kenneth A. Berlin, President and CEO of Rosetta Genomics, will present a corporate update on...

2011-07-20 08:00:00

LA JOLLA, Calif., July 20, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has identified a third microRNA target in its alliance with GlaxoSmithKline (GSK), triggering a preclinical milestone payment from GSK. This selection represents another significant milestone for Regulus in its microRNA alliance with GSK, which is focused on the discovery and...

2011-07-14 08:00:00

LA JOLLA, Calif., July 14, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has added Gregory Hannon, Ph.D. to its Scientific Advisory Board (SAB). The addition of Dr. Hannon, a researcher whose work has involved the molecular identification and characterization of the microRNA pathway, increases SAB membership to six pioneers in this area of scientific...

2011-07-06 07:01:00

PHILADELPHIA and REHOVOT, Israel, July 6, 2011 /PRNewswire/ -- Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, today announced the effectiveness of a one-for-four reverse stock split of its share capital. The reverse stock split, which was previously approved by the Company's Board of Directors, was approved by its shareholders at the 2011 Annual General Meeting of Shareholders of the Company held earlier today. The...

2011-06-28 09:12:00

PHILADELPHIA and REHOVOT, Israel, June 28, 2011 /PRNewswire/ -- Rosetta Genomics (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announces it has entered into a collaboration with the University of California, Davis ("UC Davis" or the "University") to develop and validate a microRNA profile for muscle-invasive bladder cancer (MI-BC) that is predictive of patient response to neoadjuvant chemotherapy. The collaboration allows for UC Davis...

2011-05-09 07:33:00

PHILADELPHIA and REHOVOT, Israel, May 9, 2011 /PRNewswire/ -- Rosetta Genomics (NASDAQ: ROSG) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,943,745, which is related to human hsa-miR-497 and its variants and covers the composition of matter. Human hsa-miR-497 is an important component of the Company's miRview(TM) mets and mets2 diagnostic tests for the accurate identification of the tissue of origin in Cancers of Unknown Primary...

2011-04-12 06:50:00

PHILADELPHIA and REHOVOT, Israel, April 12, 2011 /PRNewswire/ -- Rosetta Genomics, Ltd. (Nasdaq: ROSG) today announced that the Company's Board of Directors has appointed Director Brian A. Markison, former Chairman and Chief Executive Officer of King Pharmaceuticals, as Rosetta's new Board Chairman, as current chairman, Yoav Z. Chelouche, has resigned from the Company's Board and from his role as its Chairman effective today. Mr. Chelouche continues to serve as the Chairman of Rosetta...

2011-04-02 01:45:44

Biomarkers help predict lung cancer patients whose disease could spread to the brain Conducting genetic profiles using microRNA can help doctors predict which lung cancer patients are likely to also develop brain metastasis (BM), according to a study published today by Scottsdale Healthcare and the Translational Genomics Research Institute (TGen). The study identified microRNA-328 as a potential therapeutic target because of its association with the spread of cancer to the brain in patients...

2011-03-29 07:30:00

FREMONT, Calif., March 29, 2011 /PRNewswire/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art genomic analysis systems, today announced data presentations from its recently announced industry-leading high-throughput SmartChip Human microRNA Panel V2 at three key scientific conferences. Researchers in the Oncology Division at Stanford University School of Medicine will present data obtained using the SmartChip Human microRNA Panel V2 in a...